Treats major depressive disorder (MDD). ANDA 217740, held by Graviti Pharms. Trazodone Hydrochloride.
As of Nov 16, 2026, ANDA 217740 (Trazodone Hydrochloride), held by Graviti Pharms, was first approved by FDA on Aug 27, 2024, with 1 approved supplement and 0 published complete response letters.
Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2024 | Original application | Approved | None posted |
| Trazodone Hydrochloride50MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride100MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride150MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride300MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Jun 24, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 27, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters